NUP214 and acute lymphoblastic leukemia: Aim of this study was to analyze for the first time the efficacy of Imatinib, Nilotinib and GZD824 alone and in combination with several PI3K/Akt/mTOR inhibitors in three T-ALL cell lines, ALL-SIL, PEER, and BE-13 harboring NUP214-ABL1 fusion protein.